Eli Lilly and Company $LLY Stock: Bank Pictet & Cie Europe AG Reduces Holdings

Key Points

• Bank Pictet & Cie Europe AG cut its Eli Lilly stake by 16.3% in the third quarter, selling 7,313 shares and retaining 37,664 shares valued at approximately $43.6 million. Institutional investors and hedge funds still own 82.53% of the company.
• Eli Lilly insiders sold 13,500 shares worth roughly $16.0 million over the past three months through pre-arranged Rule 10b5-1 plans, while corporate insiders own only 0.14% of the stock.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $1,317.93. The company recently beat quarterly earnings and revenue estimates, though investors are monitoring pricing pressure, obesity-drug competition and the stock’s elevated valuation.

Bank Pictet & Cie Europe AG lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,664 shares of the company's stock after selling 7,313 shares during the quarter. Bank Pictet & Cie Europe AG's holdings in Eli Lilly and Company were worth $43,580,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp lifted its position in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the 2nd quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC increased its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after purchasing an additional 400,538 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LLY shares. BMO Capital Markets reissued an "outperform" rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, October 17th. Bank of America upped their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Morgan Stanley increased their price objective on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Finally, Weiss Ratings raised Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,317.93.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst target and expected earnings strength: Goldman Sachs raised its price target to $1,413 from $1,371 while maintaining a Buy rating. The firm reportedly expects Eli Lilly to beat third-quarter estimates and raise its outlook, supported by international Mounjaro growth and Zepbound volume gains. Goldman Sachs raises Eli Lilly price target
• Positive Sentiment: International manufacturing expansion: Eli Lilly signed Abu Dhabi agreements involving local packaging and advanced pharmaceutical contract manufacturing for weight-loss medicines. The company also entered a drug-delivery partnership with China’s Metis TechBio valued at up to $1.1 billion, potentially strengthening supply capacity and product-delivery capabilities. Eli Lilly Abu Dhabi packaging deal
• Positive Sentiment: Pipeline expansion: One-year Phase 3 SHINE-2 data showed Omvoh sustained clinical-remission benefits in children with ulcerative colitis, including patients who had previously failed biologic treatments. Regulatory approval could expand Lilly’s inflammatory bowel disease franchise. Pediatric ulcerative colitis data
• Neutral Sentiment: Strong growth, but pricing is a key upcoming issue: Second-quarter revenue increased 48% to approximately $23 billion as medicine volume rose 60%, while realized price per unit declined 13%. Investors will focus on whether continued demand and volume growth can offset pricing pressure when third-quarter results are released on October 29. Eli Lilly volume and pricing analysis
• Negative Sentiment: Competition and valuation risks: Novo Nordisk’s CagriSema produced 25% weight loss in women, reinforcing competitive pressure in the obesity-treatment market. After a substantial rally and record valuation, investors may also be taking profits or demanding stronger evidence that Lilly’s growth can justify its premium multiple. Novo Nordisk CagriSema results

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,271.89 on Thursday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a 50 day moving average price of $1,182.84 and a 200 day moving average price of $1,116.53. The stock has a market capitalization of $1.20 trillion, a PE ratio of 42.68, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46. Eli Lilly and Company has a 52 week low of $793.82 and a 52 week high of $1,311.75.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the firm earned $6.31 EPS. The business's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts predict that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.